CBD-FRS (Corticobasal Syndrome Functional Rating Scale)

Corticobasal Syndrome Functional Rating Scale (CBD-FRS)

The Corticobasal Syndrome Functional Rating Scale (CBD-FRS) is a specialized clinical assessment tool designed to measure functional impairment and disease severity in patients with corticobasal syndrome (CBS), a progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and movement abnormalities.

Overview

Corticobasal Syndrome Functional Rating Scale (CBD-FRS)

The Corticobasal Syndrome Functional Rating Scale (CBD-FRS) is a specialized clinical assessment tool designed to measure functional impairment and disease severity in patients with corticobasal syndrome (CBS), a progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and movement abnormalities.

Overview

CBD-FRS is used to:

• Track disease progression over time
• Assess the severity of functional impairment
• Evaluate treatment efficacy in clinical trials
• Guide clinical management decisions

Domains Assessed

Motor Function

• Limb rigidity: Assessment of axial and appendicular stiffness
• Bradykinesia: Slowed movement and reduced spontaneous activity
• Dystonia: Involuntary muscle contractions and abnormal postures
• Myoclonus: Sudden, involuntary muscle jerks
• Apraxia: Loss of learned motor movements

Cognitive Function

• Executive dysfunction: Impaired planning, reasoning, and problem-solving
• Language impairment: Progressive aphasia and verbal fluency deficits
• Visuospatial dysfunction: Spatial orientation and constructional difficulties
• Memory: Working memory and episodic memory assessment

Behavioral Changes

• Alien limb phenomena: Feeling of foreignness in affected limbs
• Apathy: Reduced initiative and motivation
• Depression: Mood changes and emotional lability
• Disinhibition: Impulsive behaviors and poor judgment

Functional Activities

• Activities of daily living (ADLs): Basic self-care tasks
• Instrumental ADLs: Complex tasks requiring multiple steps
• Mobility: Gait and balance function
• Communication: Speech and language effectiveness

Scoring System

The CBD-FRS typically uses a ordinal scale with scores ranging from 0 (normal function) to 4 or 5 (severe impairment), with higher scores indicating greater disability.

| Score | Description |
|-------|-------------|
| 0 | Normal function |
| 1 | Mild impairment |
| 2 | Moderate impairment |
| 3 | Severe impairment |
| 4 | Complete loss of function |

Individual item scores are summed to generate total scores, which can be used to:

• Track disease progression
• Compare patients across studies
• Monitor treatment response

Validation and Psychometric Properties

Reliability

• Inter-rater reliability: Demonstrates moderate to good agreement between different assessors
• Test-retest reliability: Shows acceptable consistency over short intervals
• Internal consistency: Items demonstrate coherent measurement of the underlying construct

Validity

• Content validity: Items comprehensively cover the breadth of CBS symptoms
• Construct validity: Correlates with other established measures of motor and cognitive function
• Criterion validity: Predictive of functional outcomes and disease progression

Sensitivity to Change

• Demonstrates responsiveness to disease progression over time
• Can detect clinically meaningful changes in function
• Useful for monitoring treatment effects in clinical trials

Clinical Trial Usage

CBD-FRS has been incorporated as a secondary endpoint in several clinical trials for CBS and related 4R-tauopathies, including:

• [Tau](/proteins/tau) inhibitor trials: Used to assess functional outcomes
• Neuroprotective agent studies: Monitoring disease modification
• Symptomatic treatment trials: Evaluating improvements in daily function
• Gene therapy investigations: Tracking functional endpoints

• Progressive supranuclear palsy (PSP)
• Corticobasal degeneration (CBD)
• Other 4R-tauopathies

Relationship to Other Scales

CBD-FRS shares conceptual similarities with:

• MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale): For motor assessment
• MoCA (Montreal Cognitive Assessment): For cognitive screening
• ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living): For functional assessment

Administration

Time Required

• Complete assessment: 20-30 minutes
• Training required for standardized administration

Clinician Qualifications

• Typically administered by neurologists, movement disorder specialists, or trained research coordinators
• Requires understanding of CBS presentation and progression

Frequency

• Baseline assessment at diagnosis
• Every 6-12 months for disease monitoring
• As needed for treatment decisions

Limitations

Future Directions

Emerging developments include:

• Digital CBD-FRS: Integration with wearable sensors for objective measurement
• Computerized assessment: Tablet-based administration for standardized scoring
• Item response theory: Refinement of item weighting based on psychometric analysis
• Machine learning: Predictive modeling of disease progression

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CBD-FRS (Corticobasal Syndrome Functional Rating Scale) discovered through SciDEX knowledge graph analysis: